

2019 Future of Cognitive Impairment Associated With Schizophrenia (CIAS) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/2CE77164A78EN.html>

Date: February 2019

Pages: 80

Price: US\$ 2,199.00 (Single User License)

ID: 2CE77164A78EN

Abstracts

The global demand for Cognitive Impairment Associated With Schizophrenia (CIAS) treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline companies from advancing their products into Phase 3 or Phase 4.

Cognitive Impairment Associated With Schizophrenia (CIAS) Report Description-

The 2019 pipeline study on Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline compounds.

The Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline guide presents information on all active drugs currently being developed for Cognitive

Impairment Associated With Schizophrenia (CIAS). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Cognitive Impairment Associated With Schizophrenia (CIAS) drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Cognitive Impairment Associated With Schizophrenia (CIAS) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline report includes-

An overview of Cognitive Impairment Associated With Schizophrenia (CIAS) disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline

Company wise list of Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline

Mechanism of Action wise Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline

For each pipeline candidate, the following details are provided

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials/Results

Company Overview and Recent Developments

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into companies participating in Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Cognitive Impairment Associated With Schizophrenia (CIAS) Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development
 - 3.2.1 Pre-clinical
 - 3.2.2 Discovery
 - 3.2.3 Phase
 - 3.2.4Phase
- 3.3 Pipeline Drugs in Advanced Stage of Development
 - 3.3.1 Phase
 - 3.3.2 Pre-registration
- 3.4 Companies involved in Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline, H1- 2019
- 3.5 Mechanism of Action wise Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Candidates

4 ANVYL LLC COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

- 4.1 Anvyl LLC Business Profile
- 4.2 Anvyl LLC Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
- 4.3 Drug Snapshot
 - 4.3.1 Originator

- 4.3.2 Collaborator/Co-Developer
- 4.3.3 Route of Administration
- 4.3.4 Orphan Drug/Fast Track/Special Designation
- 4.3.5 Geography
- 4.3.6 Type of Molecular Entity
- 4.3.7 Current Status
- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5 ASTELLAS PHARMA INC COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

- 5.1 Astellas Pharma Inc Business Profile
- 5.2 Astellas Pharma Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
- 5.3 Drug Snapshot
 - 5.3.1 Originator
 - 5.3.2 Collaborator/Co-Developer
 - 5.3.3 Route of Administration
 - 5.3.4 Orphan Drug/Fast Track/Special Designation
 - 5.3.5 Geography
 - 5.3.6 Type of Molecular Entity
 - 5.3.7 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6 ASTRAZENECA PLC COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

- 6.1 AstraZeneca Plc Business Profile
- 6.2 AstraZeneca Plc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
- 6.3 Drug Snapshot
 - 6.3.1 Originator
 - 6.3.2 Collaborator/Co-Developer

- 6.3.3 Route of Administration
- 6.3.4 Orphan Drug/Fast Track/Special Designation
- 6.3.5 Geography
- 6.3.6 Type of Molecular Entity
- 6.3.7 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7 AUTIFONY THERAPEUTICS LTD COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

- 7.1 Autifony Therapeutics Ltd Business Profile
- 7.2 Autifony Therapeutics Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
- 7.3 Drug Snapshot
 - 7.3.1 Originator
 - 7.3.2 Collaborator/Co-Developer
 - 7.3.3 Route of Administration
 - 7.3.4 Orphan Drug/Fast Track/Special Designation
 - 7.3.5 Geography
 - 7.3.6 Type of Molecular Entity
 - 7.3.7 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

8 BIOGEN INC COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

- 8.1 Biogen Inc Business Profile
- 8.2 Biogen Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
- 8.3 Drug Snapshot
 - 8.3.1 Originator
 - 8.3.2 Collaborator/Co-Developer
 - 8.3.3 Route of Administration

- 8.3.4 Orphan Drug/Fast Track/Special Designation
- 8.3.5 Geography
- 8.3.6 Type of Molecular Entity
- 8.3.7 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

9 BIOMED SL COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

- 9.1 Biomed SL Business Profile
- 9.2 Biomed SL Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
- 9.3 Drug Snapshot
 - 9.3.1 Originator
 - 9.3.2 Collaborator/Co-Developer
 - 9.3.3 Route of Administration
 - 9.3.4 Orphan Drug/Fast Track/Special Designation
 - 9.3.5 Geography
 - 9.3.6 Type of Molecular Entity
 - 9.3.7 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

10 BOEHRINGER INGELHEIM GMBH COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

- 10.1 Boehringer Ingelheim GmbH Business Profile
- 10.2 Boehringer Ingelheim GmbH Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
- 10.3 Drug Snapshot
 - 10.3.1 Originator
 - 10.3.2 Collaborator/Co-Developer
 - 10.3.3 Route of Administration
 - 10.3.4 Orphan Drug/Fast Track/Special Designation

- 10.3.5 Geography
- 10.3.6 Type of Molecular Entity
- 10.3.7 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details
- 10.7 Latest Drug Developments

11 BRISTOL-MYERS SQUIBB CO COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

- 11.1 Bristol-Myers Squibb Co Business Profile
- 11.2 Bristol-Myers Squibb Co Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
- 11.3 Drug Snapshot
 - 11.3.1 Originator
 - 11.3.2 Collaborator/Co-Developer
 - 11.3.3 Route of Administration
 - 11.3.4 Orphan Drug/Fast Track/Special Designation
 - 11.3.5 Geography
 - 11.3.6 Type of Molecular Entity
 - 11.3.7 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details
- 11.7 Latest Drug Developments

12 CADENT THERAPEUTICS COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

- 12.1 Cadent Therapeutics Business Profile
- 12.2 Cadent Therapeutics Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
- 12.3 Drug Snapshot
 - 12.3.1 Originator
 - 12.3.2 Collaborator/Co-Developer
 - 12.3.3 Route of Administration
 - 12.3.4 Orphan Drug/Fast Track/Special Designation
 - 12.3.5 Geography

- 12.3.6 Type of Molecular Entity
- 12.3.7 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

13 ELI LILLY AND CO COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

- 13.1 Eli Lilly and Co Business Profile
- 13.2 Eli Lilly and Co Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
- 13.3 Drug Snapshot
 - 13.3.1 Originator
 - 13.3.2 Collaborator/Co-Developer
 - 13.3.3 Route of Administration
 - 13.3.4 Orphan Drug/Fast Track/Special Designation
 - 13.3.5 Geography
 - 13.3.6 Type of Molecular Entity
 - 13.3.7 Current Status
- 13.4 Drug Overview
- 13.5 Drug Mechanism of Action
- 13.6 Clinical/Pre-clinical Trial Details
- 13.7 Latest Drug Developments

14 F. HOFFMANN-LA ROCHE LTD COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

- 14.1 F. Hoffmann-La Roche Ltd Business Profile
- 14.2 F. Hoffmann-La Roche Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
- 14.3 Drug Snapshot
 - 14.3.1 Originator
 - 14.3.2 Collaborator/Co-Developer
 - 14.3.3 Route of Administration
 - 14.3.4 Orphan Drug/Fast Track/Special Designation
 - 14.3.5 Geography
 - 14.3.6 Type of Molecular Entity

- 14.3.7 Current Status
- 14.4 Drug Overview
- 14.5 Drug Mechanism of Action
- 14.6 Clinical/Pre-clinical Trial Details
- 14.7 Latest Drug Developments

15 HEPTARES THERAPEUTICS LTD COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

- 15.1 Heptares Therapeutics Ltd Business Profile
- 15.2 Heptares Therapeutics Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
- 15.3 Drug Snapshot
 - 15.3.1 Originator
 - 15.3.2 Collaborator/Co-Developer
 - 15.3.3 Route of Administration
 - 15.3.4 Orphan Drug/Fast Track/Special Designation
 - 15.3.5 Geography
 - 15.3.6 Type of Molecular Entity
 - 15.3.7 Current Status
- 15.4 Drug Overview
- 15.5 Drug Mechanism of Action
- 15.6 Clinical/Pre-clinical Trial Details
- 15.7 Latest Drug Developments

16 INTRA-CELLULAR THERAPIES INC COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

- 16.1 Intra-Cellular Therapies Inc Business Profile
- 16.2 Intra-Cellular Therapies Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
- 16.3 Drug Snapshot
 - 16.3.1 Originator
 - 16.3.2 Collaborator/Co-Developer
 - 16.3.3 Route of Administration
 - 16.3.4 Orphan Drug/Fast Track/Special Designation
 - 16.3.5 Geography
 - 16.3.6 Type of Molecular Entity
 - 16.3.7 Current Status

- 16.4 Drug Overview
- 16.5 Drug Mechanism of Action
- 16.6 Clinical/Pre-clinical Trial Details
- 16.7 Latest Drug Developments

17 IPROTEOS SL COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

- 17.1 Iproteos SL Business Profile
- 17.2 Iproteos SL Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
- 17.3 Drug Snapshot
 - 17.3.1 Originator
 - 17.3.2 Collaborator/Co-Developer
 - 17.3.3 Route of Administration
 - 17.3.4 Orphan Drug/Fast Track/Special Designation
 - 17.3.5 Geography
 - 17.3.6 Type of Molecular Entity
 - 17.3.7 Current Status
- 17.4 Drug Overview
- 17.5 Drug Mechanism of Action
- 17.6 Clinical/Pre-clinical Trial Details
- 17.7 Latest Drug Developments

18 PFIZER INC COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

- 18.1 Pfizer Inc Business Profile
- 18.2 Pfizer Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
- 18.3 Drug Snapshot
 - 18.3.1 Originator
 - 18.3.2 Collaborator/Co-Developer
 - 18.3.3 Route of Administration
 - 18.3.4 Orphan Drug/Fast Track/Special Designation
 - 18.3.5 Geography
 - 18.3.6 Type of Molecular Entity
 - 18.3.7 Current Status
- 18.4 Drug Overview

- 18.5 Drug Mechanism of Action
- 18.6 Clinical/Pre-clinical Trial Details
- 18.7 Latest Drug Developments

19 SK BIOPHARMACEUTICALS CO LTD COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

- 19.1 SK Biopharmaceuticals Co Ltd Business Profile
- 19.2 SK Biopharmaceuticals Co Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
- 19.3 Drug Snapshot
 - 19.3.1 Originator
 - 19.3.2 Collaborator/Co-Developer
 - 19.3.3 Route of Administration
 - 19.3.4 Orphan Drug/Fast Track/Special Designation
 - 19.3.5 Geography
 - 19.3.6 Type of Molecular Entity
 - 19.3.7 Current Status
- 19.4 Drug Overview
- 19.5 Drug Mechanism of Action
- 19.6 Clinical/Pre-clinical Trial Details
- 19.7 Latest Drug Developments

20 SPHERIUM BIOMED SL COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

- 20.1 Spherium Biomed SL Business Profile
- 20.2 Spherium Biomed SL Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
- 20.3 Drug Snapshot
 - 20.3.1 Originator
 - 20.3.2 Collaborator/Co-Developer
 - 20.3.3 Route of Administration
 - 20.3.4 Orphan Drug/Fast Track/Special Designation
 - 20.3.5 Geography
 - 20.3.6 Type of Molecular Entity
 - 20.3.7 Current Status
- 20.4 Drug Overview
- 20.5 Drug Mechanism of Action

20.6 Clinical/Pre-clinical Trial Details

20.7 Latest Drug Developments

21 SUVEN NEUROSCIENCES INC COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

21.1 Suven Neurosciences Inc Business Profile

21.2 Suven Neurosciences Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details

21.3 Drug Snapshot

21.3.1 Originator

21.3.2 Collaborator/Co-Developer

21.3.3 Route of Administration

21.3.4 Orphan Drug/Fast Track/Special Designation

21.3.5 Geography

21.3.6 Type of Molecular Entity

21.3.7 Current Status

21.4 Drug Overview

21.5 Drug Mechanism of Action

21.6 Clinical/Pre-clinical Trial Details

21.7 Latest Drug Developments

22 TAKEDA PHARMACEUTICAL CO LTD COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

22.1 Takeda Pharmaceutical Co Ltd Business Profile

22.2 Takeda Pharmaceutical Co Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details

22.3 Drug Snapshot

22.3.1 Originator

22.3.2 Collaborator/Co-Developer

22.3.3 Route of Administration

22.3.4 Orphan Drug/Fast Track/Special Designation

22.3.5 Geography

22.3.6 Type of Molecular Entity

22.3.7 Current Status

22.4 Drug Overview

22.5 Drug Mechanism of Action

22.6 Clinical/Pre-clinical Trial Details

22.7 Latest Drug Developments

23 VANDA PHARMACEUTICALS INC COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

23.1 Vanda Pharmaceuticals Inc Business Profile

23.2 Vanda Pharmaceuticals Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details

23.3 Drug Snapshot

23.3.1 Originator

23.3.2 Collaborator/Co-Developer

23.3.3 Route of Administration

23.3.4 Orphan Drug/Fast Track/Special Designation

23.3.5 Geography

23.3.6 Type of Molecular Entity

23.3.7 Current Status

23.4 Drug Overview

23.5 Drug Mechanism of Action

23.6 Clinical/Pre-clinical Trial Details

23.7 Latest Drug Developments

24. LATEST COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) DRUG PIPELINE DEVELOPMENTS, 2019

25. APPENDIX

25.1 About Us

25.2 Sources and Methodology

25.3 Contact Information

I would like to order

Product name: 2019 Future of Cognitive Impairment Associated With Schizophrenia (CIAS) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/2CE77164A78EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2CE77164A78EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970